Pharmaceutisch weekblad

, Volume 1, Issue 1, pp 705–711 | Cite as

Monitoring of free plasma propranolol

  • P. Vermeij
  • P. A. Van Zwieten
Original Articles


Evidence exists that the free plasma propranolol concentration may correlate with the pharmacological effect in a better way than the total plasma concentration. Three approaches to obtain the free fraction were compared,viz. 1) equilibrium dialysis, 2) calculation from the ratio erythrocyte concentration: plasma concentration ([R]/[P]-ratio) and 3) derivation from the salivary concentration. It is concluded that the [R]/[P]-ratio has a linear relationship to the free propranolol concentration, described by the equation [R]/[P]=6.9 (1-f)−0.25 (n= 46, r=+0.956; p<0.01). This method is reliable and simple to perform. No differences were seen between fresh blood samples, 14 days oldAcd-blood or artificial blood. The presence of various other drugs (4-hydroxypropranolol, chlorthalidone, clonidine, K-canrenoate, hydrallazine) did not interfere with the relationship between [R]/[P] and (1-f). A constant relationship between the salivary and free plasma propranolol concentrations does not exist, mainly because of buccal contamination. Equilibrium dialysis may pose an analytical problem. Therefore, the authors prefer the method based on the [R]/[P]versus (1-f) relationship.


Propranolol Clonidine Free Fraction Chlorthalidone Equilibrium Dialysis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Appelgren, C., K. O. Borg, R. Elofsson andK. A. Johansson (1974)Acta Pharm. Suecica II, 325–332.Google Scholar
  2. Cotham, R. H., andD. G. Shand (1975)Clin. Pharmacol. Therap. 18, 535–538.CrossRefGoogle Scholar
  3. Dam, J. G. Van, andA. G. Van Loenen (1978)Pharm. Weekblad 113, 65–75.Google Scholar
  4. Dollery, C. T. (1976) in:Beta-adrenoceptor blocking agents. North-Holland Publishing Company, Amsterdam-Oxford, p. 291.Google Scholar
  5. Evans, G. H., andD. G. Shand (1973)Clin. Pharmacol. Therap. 14, 494–500.CrossRefGoogle Scholar
  6. Evans, G. H., A. S. Nies andD. G. Shand (1973)J. Pharmacol. Exptl. Therap. 186, 114–122.Google Scholar
  7. Johnsson, G., andC. -G. Regårdh (1976)Clin. Pharmacokin. 1, 233–263.CrossRefGoogle Scholar
  8. Kaye, C. M., D. Orton, E. A. Taylor andC. Brunell (1977)Brit. J. Clin. Pharm. 4, 724P.Google Scholar
  9. Kurz, H., H. Trunk andB. Weitz (1977)Arzneimittelforsch. (Drug Research) 27, 1373–1380.Google Scholar
  10. Levy, G. (1976)J. Pharm. Sci. 65, 1264–1265.CrossRefPubMedGoogle Scholar
  11. Melander, A., K. Danielson, B. Schersten andE. Wahlin (1977)Clin. Pharmacol. Therap. 22 108–112.CrossRefGoogle Scholar
  12. Odar-Cederlöf, I., andBorgå (1976)Clin. Pharmacol. Therap. 20, 36–47.CrossRefGoogle Scholar
  13. Piafsky, M., andBorgå (1977)Clin. Pharmacol. Therap. 22, 545–549.CrossRefGoogle Scholar
  14. Ritschel, W. (1976)Handbook of basic Pharmacokinetics. Drug Intelligence Publications Inc., Hamilton, III. p. 117.Google Scholar
  15. Shand, D. G., M. Frisk-Holmberg, D. Mcdevitt, K. Sherman andJ. Hollifield (1975) in:Pathophysiology and Management of Arterial Hypertension. Lindgren & Söner, Mölndal, p. 175–182.Google Scholar
  16. Vermeij, P. (1977)Kinetische Aspecten van enige β-blokkeerders. Ph. D. Thesis, University of Amsterdam.Google Scholar
  17. Walle, Th. (1974)J. Pharm. Sci. 63, 1885–1891.CrossRefPubMedGoogle Scholar

Copyright information

© Bohn, Scheltema & Holkema 1979

Authors and Affiliations

  • P. Vermeij
    • 1
  • P. A. Van Zwieten
    • 2
  1. 1.PharmacyAndreas ZiekenhuisAmsterdamThe Netherlands
  2. 2.Department of Pharmacy, Division of PharmacotherapyUniversity of AmsterdamAmsterdamThe Netherlands

Personalised recommendations